Glaxosmithkline


Gloomy outlook for FY21; R&D setbacks worrisome

19/02/21 -"Along the near-to mid-term headwinds — pandemic-related disruptions and rising competition — the dividend cut from FY22 onwards is also a cause of worry. Thus, we trim our target price by 11%."

Pages
67
Language
English
Published on
19/02/21
You may also be interested by these reports :
25/02/21
Bayer really needs a kind of breakthrough or a brilliant idea to change the sentiment on the name. We understand glyphosate-related issues and the ...

24/02/21
FY20 sales and operating profit targets were exceeded, led by higher Darzalex royalties and lower R&D costs. Given its convenience dosing, Darzalex ...

19/02/21
Along the near-to mid-term headwinds — pandemic-related disruptions and rising competition — the dividend cut from FY22 onwards is also a cause of ...

15/02/21
Benefiting from the resilience of the oncology franchisee, sales momentum accelerated in Q4 and the FY20 targets were exceeded. Assuming the phased ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO